Fierce Pharma

OCTOBER 6, 2023

With the new real estate, Lotte plans to build out three separate bio plants by 2030. . | Lotte this week unveiled a land purchase agreement with the Incheon Free Economic Zone Authority in Incheon, Korea.

Manufacturing 287

Manufacturing 287

Fierce Pharma

JUNE 28, 2023

With that new investment, the company is raising its commitment to plant and nurture 200 million trees across six continents by 2030—the same year AstraZeneca aims to halve its environmental footprint across its entire value chain.

263

263

Fierce Pharma

JANUARY 24, 2023

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says zbecker Tue, 01/24/2023 - 09:14

Sales 246

Sales 246

Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Sales 262

Sales 262

Fierce Pharma

FEBRUARY 9, 2023

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

246

246

Fierce Pharma

NOVEMBER 1, 2024

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | So far, argenx's Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an FDA approval in (..)

FDA 308

FDA Patients 308

Fierce Pharma

JUNE 23, 2025

Fueled by sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin, according to data analytics specialist Evaluate Pharma in its 2030 projection.

Prescription 138

Prescription Sales Pharma 138

Fierce Pharma

OCTOBER 16, 2024

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. |

287

287

Fierce Pharma

OCTOBER 2, 2023

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 170

Leads Sales Pharma 170

Fierce Pharma

JUNE 12, 2023

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

Sales goal 354

Sales goal Sales 354

pharmaphorum

JUNE 30, 2025

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

Manufacturing 98

Manufacturing 98

pharmaphorum

MARCH 1, 2024

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

133

133

MedCity News

SEPTEMBER 6, 2024

By 2030, the U.S. expects shortages of 200,000 nurses and 124,000 physicians snd similar shortages are already being felt in the U.K. and elsewhere. Here’s how to build and train a modern healthcare workforce in the age of AI The post Can AI Help Fix Our Demographic Time Bomb? appeared first on MedCity News.

Physicians 306

Physicians Training Healthcare Healthcare 306

Fierce Pharma

JUNE 13, 2024

Pfizer's oncology division plans to have eight blockbusters by 2030, with contributions from each of its four focused therapeutic areas.

287

287

European Pharmaceutical Review

JUNE 2, 2025

The post R&D and tech innovation boosting biopharmaceutical market to 2030 appeared first on European Pharmaceutical Review. Key players in the global biopharmaceutical market include AbbVie Inc., AstraZeneca, Eli Lilly and Co., Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer Inc.,

Marketing 52

Marketing Medicine Pharmaceutical 52

pharmaphorum

MAY 21, 2024

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

119

119

Fierce Pharma

JUNE 17, 2024

As part of Vision 2030, argenx will touch on its continuing commitment to tackle severe autoimmune diseases with Vyvgart. As argenx homes in on the next indication for its pipeline-in-a-product Vyvgart (efgartigimod), the company is preparing for the next leg of its commercial journey. |

130

130

MedCity News

FEBRUARY 15, 2023

Analysts predict that disruptors could own as much as 30% of the $260 billion primary care market by 2030.

Healthcare 306

Healthcare Healthcare Marketing Medical 306

Fierce Pharma

JUNE 7, 2024

With 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. | The launches are part of the company's wider plan to bring 25 new products to the market by 2030.

Marketing 242

Marketing 242

Fierce Pharma

FEBRUARY 7, 2024

Overall, the company is pushing to generate 30% of its revenues from oncology by 2030. In 2023, the number was 11%.

294

294

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Marketing 260

Marketing Healthcare Healthcare 260

PharmExec

MAY 20, 2025

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk through free LDL-C testing, public-private partnerships, and implementation science initiativesall aimed at cutting CV events in half by 2030.

Medicine 40

Medicine 40

PharmaVoice

APRIL 21, 2025

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

Marketing 221

Marketing Competition 221

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Marketing 98

Marketing Biopharma Pharmaceutical Pharma 98

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Sales 98

Sales Biopharma Manufacturing Pharma 98

European Pharmaceutical Review

MARCH 28, 2024

billion by 2030. percent between 2024-2030. by 2030 appeared first on European Pharmaceutical Review. The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. This figure is projected to increase to $38.1 PerkinElmer, Inc.

Pharmaceutical 98

Pharmaceutical Marketing Pharma Management 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Marketing 98

Marketing Manufacturing Management Pharmaceutical manufacturing 98

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 98

Sales Pharma Government Medicine 98

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Marketing 96

Marketing Pharmaceutical Manufacturing Pharma 96

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Manufacturing 98

Manufacturing Marketing Side effects Transportation 98

PharmaVoice

MAY 23, 2024

Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

Sales goal 130

Sales goal Sales Pharma 130

Pharmaceutical Technology

DECEMBER 10, 2024

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia - is forecast to grow from $582m in 2020 to $6.2bn in 2030 at a compound annual growth rate of 26.7%, with the paediatric and adult segments (..)

Marketing 59

Marketing 59

Pharmaceutical Commerce

JULY 3, 2025

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.

Manufacturing 52

Manufacturing Pharma Patients 52

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

Sales 103

Sales 103

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Marketing 52

Marketing Management Patients Pharmaceutical 52

Fierce Pharma

AUGUST 4, 2023

The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. For years, Gilead has been on a mission to become a power player in oncology. | This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

130

130